The 100-day PSA: Usefulness as surrogate end point for biochemical disease-free survival after definitive radiotherapy of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 7, Issue 3, 2004, Pages 263-267

  Johnstone, Peter A S ^a,b,c   Williams, S R ^a   Riffenburgh, R H ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY CLINIC   (United States)

Author keywords

Follow up regimens; Prognostic factors; Prostate specific antigen

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CALCULATION; CANCER HORMONE THERAPY; CANCER SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RELIABILITY; BLOOD; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; TIME;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 16644390689     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500736     Document Type: Article

References (32)

1. Powell C et al. Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy. J Urol 1997; 157: 1754-1759.
2. Gray CL, Powell CR, Riffenburgh RH, Johnstone PAS. 20-year outcome for patients withT1-3N0 surgically staged prostate cancer treated with external beam radiation therapy. J Urol 2001; 166: 116-118.
3. Vollmer RT, Montana GS. The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer. Clin Cancer Res 1999; 5: 4119-4125.
4. 0 prostate cancer. Radiat Oncol Invest 1998; 6: 103-108.
5. Walsh PC. Editorial: Localized prostate cancer - mortality and morbidity. J Urol 1997; 157: 1773.
6. Ritter MA et al. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1990; 10: 1208-1217.
7. Zagars GK, Pollack A. The rise and fall of prostate-specific antigen: kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 1993; 72: 832-842.
8. D'Amico AV, Hanks GE. Linear regression analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993; 72: 2638-2643.
9. Cox RS, Kaplan ID, Bagshaw MA. Prostate-specific antigen kinetics after external beam irradiation for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1993; 8: 23-31.
10. Pollack A, Zagars GK, Kavadi VS. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 1994; 74: 670-678.
11. Hanlon AL, Moore DF, Hanks GE. Modeling post-radiation prostate-specific antigen dynamics. Predictors of rising post-nadir slope suggest cure in men who remain biochemically free of prostate cancer. Cancer 1998; 83: 130-134.
12. Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 297-303.
13. Chandra A, Levy LB, Kuban DA. PSA nadir and time to nadir as independent predictors of PSA failure-free survival in prostate carcinoma. Proc RSNA 2002; 225 (P): 320-321, (#334).
14. Aref I, Eapen L, Agboola O, Bross P. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma. Radiother Oncol 1998; 48: 203-207.
15. Crook JM et al. Serum prostate-specific antigen profile following radiotherapy for prostate cancer Implications for patterns of failure and definition of cure. Urology 1998; 51: 566-572.
16. Johnstone PA, Buser AM, Riffenburgh RH. Time to nadir of serum prostate specific antigen (PSA) is independent of outcome for patients with prostate cancer (CaP) treated with radiotherapy. Proc ASCO 1999; 18: 342a (#1318).
17. Bauer JJ et al. Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progresion after radical prostatectomy for prostate cancer. Military Med 1998; 163: 615-619.
18. D'Amico AV et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17: 168-172.
19. Kattan MW et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000; 18: 3352-3359.
20. Zagars GK, Pollack A. The serum prostate-specific antigen level three months after radiotherapy for prostate cancer an early indicator of response to treatment. Radiother Oncol 1994; 30: 121-127.
21. American Society for Therapeutic Radiology and Oncology. American Society for Therapeutic Radiology and Oncology Consensus Panel Guidelines for PSA following radiation therapy. Int J Radat Oncol Biol Phys 1997; 37: 1035-1041.
22. Brethauer SA, Magrino TJ, Riffenburgh RH, Johnstone PAS. Management of recurrent colorectal carcinoma. Colorectal Dis 2002; 4: 246-253.
23. O'Meara WP, Thiringer JK, Johnstone PAS. Follow-up of head and neck cancer patients post-radiotherapy. Radiother Oncol 2003; 66: 323-326.
24. Johnstone PAS, McFarland JT, Riffenburgh RH, Amling CL. Efficacy of the digital rectal examination after radiotherapy for prostate cancer. J Urol 2001; 166: 1684-1687.
25. Huben RP. Prostate carcinoma. In: Johnson FE, Virgo KS (eds) Cancer Patient Follow-up. Mosby: St. Louis, MO, 1997; pp 378-389.
26. Dalbagni G, Fair WR. Prostate cancer counterpoint. In: Johnson FE, Virgo KS (eds). Cancer Patient Follow-up. Mosby: St. Louis, MO, 1997; pp 389-394.
27. Kakizoe T. Prostate cancer: Counterpoint. In: Johnson FE, Virgo KS (eds). Cancer Patient Follow-up. Mosby: St. Louis, MO, 1997; pp 395-400.
28. Takayama TK, Lange PH. Prostate cancer: Counterpoint. In: Johnson FE, Virgo KS (eds). Cancer Patient Follow-up. Mosby: St. Louis, MO, 1997; pp 400-405.
29. Oh J et al. Current followup strategies after radical prostatectomy: A survey of American Urological Association urologists. J Urol 1999; 161: 520-523.
30. Jani AB et al. PSA based outcome analysis after radiation therapy for prostate cancer: A new definition of biochemical failure after intervention. Urology 1999; 54: 700-705.
31. Johnstone PAS et al. The effect of ethnicity on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal access healthcare system: A Radiation Oncology report of the Department of Defense Center for Prostate Disease Research. Radiology 2002; 225: 420-426.
32. Johnstone PAS et al. The effect of age on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: A radiation oncology report of the Department of Defense Center for Prostate Disease Research. Int J Radiat Oncol Biol Phys 2003; 55: 964-969.